Home Articles List Article Information
ALEXMED ePosters
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Morsi, M., Bessa, A., Ibrahim, T., Mohamed, M. (2022). INTRACAMERAL INJECTION OF DEXAMETHASONE VERSUS INTRAVITREAL INJECTION OF RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS UNDERGOING CATARACT SURGERY. ALEXMED ePosters, 4(2), 8-9. doi: 10.21608/alexpo.2022.134991.1397
Mahmoud Hassan Morsi; Amr Bessa; Tamer Moussa Ibrahim; Marwa Mostafa Ali Mohamed. "INTRACAMERAL INJECTION OF DEXAMETHASONE VERSUS INTRAVITREAL INJECTION OF RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS UNDERGOING CATARACT SURGERY". ALEXMED ePosters, 4, 2, 2022, 8-9. doi: 10.21608/alexpo.2022.134991.1397
Morsi, M., Bessa, A., Ibrahim, T., Mohamed, M. (2022). 'INTRACAMERAL INJECTION OF DEXAMETHASONE VERSUS INTRAVITREAL INJECTION OF RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS UNDERGOING CATARACT SURGERY', ALEXMED ePosters, 4(2), pp. 8-9. doi: 10.21608/alexpo.2022.134991.1397
Morsi, M., Bessa, A., Ibrahim, T., Mohamed, M. INTRACAMERAL INJECTION OF DEXAMETHASONE VERSUS INTRAVITREAL INJECTION OF RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS UNDERGOING CATARACT SURGERY. ALEXMED ePosters, 2022; 4(2): 8-9. doi: 10.21608/alexpo.2022.134991.1397

INTRACAMERAL INJECTION OF DEXAMETHASONE VERSUS INTRAVITREAL INJECTION OF RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS UNDERGOING CATARACT SURGERY

Article 1, Volume 4, Issue 2, June 2022, Page 8-9  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2022.134991.1397
View on SCiNiTO View on SCiNiTO
Authors
Mahmoud Hassan Morsi1; Amr Bessa2; Tamer Moussa Ibrahim3; Marwa Mostafa Ali Mohamed email 1
1Department of Ophthalmology, Faculty of Medicine, Alexandria University
2Ophthalmology Department, Faculty of Medicine, Alexandria University, Egypt
3Ophthalmology Deparment- Faculty of Medicine- Alexandria University
Abstract
Diabetes mellitus (DM) comprises a group of disorders of carbohydrate and fat metabolism manifesting hyperglycemia. Diabetic retinopathy is a micro‌angiopathy resulting from the chronic effects of the disease, retinal vascular changes dominate the clinical manifestations of disease and are directly implicated in the macular edema and neovascularization that represent the principal causes of vision loss. cataract develops and progresses more frequently, rapidly, and at an earlier age in patients with diabetes. Diabetic ME seems to be the most common reason of poor visual outcomes in diabetic patients after cataract surgery. Anti-VEGF is the current first-line therapy for CI-DME. Steroids are a suitable treatment option for DME, due to their anti-inflammatory properties. Intracameral dexamethasone injection appears to be an effective and safe practice to be adopted in any diabetic patient undergoing cataract surgery.
AIM OF THE WORK:
The aim of the present study was to compare the effect of intracameral dexamethasone 0.4 mg/0.1 ml injection at the conclusion of cataract surgery extraction to diabetic patients with diabetic macular edema on the central macular thickness (calculated by preoperative and postoperative OCT) to the effect of intravitreal Ranibizumab injection at the conclusion of cataract extraction surgery to diabetic patients with diabetic macular edema on the central macular thickness (calculated by preoperative and postoperative OCT).
Keywords
Diabetes mellitus (DM); Anti-VEGF; Intracameral dexamethasone
Supplementary Files
Statistics
Article View: 180